Abstracts tagged "classification criteria and serologic tests"

Abstract Number: 1154 • 2017 ACR/ARHP Annual Meeting
Use of Including Serum Ferritin and Heme Oxygenase 1 in the Yamaguchi’s Classification for Adult-Onset Still’s Disease: A Multicenter Retrospective Study
Yohei Kirino¹, Yasushi Kawaguchi², Yoshifumi Tada³, Hiroshi Tsukamoto⁴, Toshiyuki Ota⁵, Masahiro Iwamoto⁶, Hiroki Takahashi⁷, Kohei Nagasawa⁸, Syuji Takei⁹, Takahiko Horiuchi¹⁰, Hisae Ichida², Seiji Minota¹¹, Atsuhisa Ueda¹, Akihide Ohta¹² and Yoshiaki Ishigatsubo¹³, ¹Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Department of Internal Medicine, Division of Rheumatology, Saga University, Saga, Japan, ⁴Department of medicine and biosystemic science, Kyushu University Hospital, Fukuoka, Japan, ⁵Department of Rheumatology, Iizuka Hospital, Iizuka, Japan, ⁶Deivision of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, ⁷Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan, ⁸Rheumatic Disease Center, Sawara Hospital, Sawara, Japan, ⁹Pediatrics of Developmental Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan, ¹⁰Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ¹¹Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, ¹²Saga University School of Medicine, Saga, Japan, ¹³Yokohama City University, Yokohama, Japan
Background/Purpose: Yamaguchi’s criteria for classification of adult-onset Still’s disease (AOSD) has been widely applied in clinic despite it was established decades ago. However, hyperferritinemia, which…
Abstract Number: 2543 • 2014 ACR/ARHP Annual Meeting
Anti-Ro/SSA Positive Incomplete Sjögren’s Syndrome
R. Hal Scofield¹, Anne Igoe², Donald U Stone³, Lida Radfar⁴, Kimberly S. Hefner⁵, David M. Lewis⁶, Stephen Young⁶, Judy Harris⁷, Kiely Grundahl⁷, Biji T. Kurien⁸, Jacen Maier-Moore⁹, Kristi A. Koelsch¹⁰, James Chodosh¹¹, Nelson L. Rhodus¹², Raj Gopalakrishnan¹³, Barbara M. Segal¹⁴, A. Darise Farris¹⁵, Courtney G. Montgomery¹⁶, Christopher J. Lessard¹⁷, Kathy L. Sivils¹⁸ and Astrid Rasmussen⁷, ¹US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ²Metro Health, Cleveland, OH, ³Dean McGee Eye Institute, Oklahoma City, OK, ⁴College of Dentristry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁶College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁷Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, ⁹Dept. of Clinical Laboratory Science, University of Texas at El Paso, El Paso, TX, ¹⁰Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Okalahoma City, OK, ¹¹Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ¹²University of Minnesota, Minneapolis, MN, ¹³Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ¹⁴Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹⁵Arthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁷825 N.E. 13th St., Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is a systemic disease characterized by dry eyes and mouth resulting from immune mediated damage and dysfunction of the lacrimal and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].